ICU Medical Inc (ICUI)

Sep 24, 2026

Argus has issued a stock forecast for ICU Medical, Inc. (ICUI), raising its target price to $169.00 from a current price of $166.02. The report, dated September 23, 2026, describes ICU Medical as a California-based pure-play infusion therapy company.

Sep 22, 2026

ICU Medical Inc (ICUI) shares recently rose 3.7% to $160.98, significantly above its GF Value™ estimate of $121.40, indicating it is "Significantly Overvalued." The company has a strong GF Score™ of 83/100, driven by profitability and momentum, but its valuation rank is weak, and insiders have sold $8.3 million in shares with no buying activity, suggesting caution for investors.

Sep 21, 2026

Otsuka ICU Medical LLC has issued a recall for one lot of 0.9% Sodium Chloride Injection, USP (saline) after a customer discovered a bag of concentrated potassium chloride inside a saline-labeled overwrap. The recall, affecting lot 1042188, targets hospitals and clinics, though no adverse events have been reported. The primary safeguard against accidental administration is the clear labeling on the inner potassium chloride bag, requiring healthcare professionals to check before use.

Sep 17, 2026

ICU Medical's CFO, Brian Michael Bonnell, sold 6,381 shares of common stock for $1.1 million on September 1, 2026, as part of a pre-established Rule 10b5-1 trading plan. Despite the sale, Bonnell retains 56,062 shares valued at approximately $9.5 million, indicating continued confidence in the company. The sale is considered routine and not a cause for alarm, especially given ICU Medical's recent positive financial performance and stock growth.